Edwards Lifesciences Corporation Profile Avatar - Palmy Investing

Edwards Lifesciences Corporation

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products…

Medical - Devices
US, Irvine [HQ]
Financials

Analysts

Reported
Past Estimate Consensus
Future Estimate Consensus
EPS Revenue EBITDA EBIT SGA
Download
FY EPS Revenue [mil.] Profit [mil.] EBITDA [mil.] EBIT [mil.] Expenses · SGA [mil.]
E E E E E E
2014 0.5900 1.390 2,045 2,084 391 697 387 1,057 454 426 745 759
2015 1.2700 0.753 2,322 2,477 811 464 -176 662 492 602 858 797
2016 0.7700 0.954 2,493 2,953 494 541 649 787 642 744 850 859
2017 0.8900 1.253 2,963 3,392 569 511 885 1,035 818 917 904 892
2018 0.9800 1.566 3,435 3,806 622 666 999 803 1,022 688 984 1,025
2019 1.1500 1.868 3,722 4,320 722 983 1,390 1,205 1,072 1,077 1,088 1,169
2020 1.6800 1.889 4,348 4,385 1,046 742 1,330 926 1,238 803 1,242 1,191
2021 1.3200 2.263 4,386 5,259 823 1,390 1,735 1,701 1,316 1,564 1,228 1,407
2022 2.4100 2.460 5,232 5,368 1,503 1,529 1,483 1,895 1,586 1,745 1,493 1,659
2023 2.4600 2.509 5,382 5,969 1,521 1,402 1,829 2,085 1,789 1,919 1,567 1,825
2024 2.3100 2.572 6,004 5,836 1,402 1,567 1,945 1,924 1,729 1,757 1,823 1,688
2025 - 2.446 - 5,908 - 1,493 - 1,948 - 1,779 - 1,708
2026 - 2.F12X/td> - 2.F12X/td> - 2.F12X/td> - 2.F121/td> - 2.F121 - 2.F121
2027 - 1.F13X/td> - 1.F13X/td> - 1.F13X/td> - 1.F131/td> - 1.F131 - 1.F131
2028 - 0.F14X/td> - 0.F14X/td> - 0.F14X/td> - 0.F141/td> - 0.F141 - 0.F141
End of EW's Analysis
CIK: 1099800 CUSIP: 28176E108 ISIN: US28176E1082 LEI: - UEI: -
Secondary Listings
EW has no secondary listings inside our databases.